Viropil
Dolutegravir · Lamivudine · Tenofovir Disoproxil
Dolutegravir and lamivudine tablets for HIV-1 infection. It blocks two different steps in the HIV lifecycle.
- Category
- HIV Management
- Active ingredients
- Dolutegravir · Lamivudine · Tenofovir Disoproxil
- Route
- Oral use
- Form
- Tablet
- Strengths
- 50mg + 300mg + 300mg
Prescription and consultation requirements for Viropil vary by destination and are determined by the fulfilment partner.
Viropil details
- Alternative names
- dolutegravir, lamivudine, tenofovir
- Therapeutic class
- Integrase Inhibitor, Nucleoside Analog Combination
- Pharmacological class
- Antiretroviral Combination
- Contraindications
- severe renal impairment; concurrent dofetilide use; severe hepatic failure
- Minor side effects
- headache; nausea; insomnia
- Moderate side effects
- diarrhoea; fatigue; elevated cholesterol
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Emcure Pharmaceuticals
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Antacids; Rifampin; Carbamazepine
- Age restrictions
- Approved for adults weighing over forty kilograms.
Serious side effects
lactic acidosis, requires immediate medical attention; hepatotoxicity, requires immediate medical attention; severe acute hepatitis B flare, requires immediate medical attention
Patient summary
Dolutegravir and lamivudine tablets for HIV-1 infection. It blocks two different steps in the HIV lifecycle.
Mechanism of action
Combines three active agents to block retroviral integration and reverse transcription, halting viral chain growth.
Pregnancy and breastfeeding
Pregnancy: Use if benefit outweighs risk. Avoid in early pregnancy. Breastfeeding: Not recommended.